JP Morgan Healthcare Conference Day 4: Gritstone Bio, Rain Therapeutics, Aprea Therapeutics
Highlights of the fourth day included details on Gritstone's neoantigen cancer vaccines, Rain's milademetan, and Aprea's eprenetapopt.
JP Morgan Healthcare Conference Day 3: Iovance, Elevation Oncology, Autolus, and More
Highlights of the third day included details on Iovance's regulatory progress on its TIL therapy, Elevation's seribantumab, and Precigen's UltraCAR-T therapies.
Precision Oncology in 2021: Growing Complexity, Refining Liquid Biopsy Use, Focus on Access Gaps
Amid new treatment options and a growing list of actionable biomarkers, the field last year also focused on the need to better support oncologists and address access gaps for patients.
JP Morgan Healthcare Conference Day 2: Ideaya, Amgen, Revolution Medicines, Monte Rosa, and More
On the second day of the conference, several pharmas discussed KRAS inhibitor programs and MDx firms detailed plans to further expand their cancer testing business.
JP Morgan Healthcare Conference Day 1: Novartis, Gilead, Johnson & Johnson, EQRx, Mirati, and More
Companies provided updates on precision oncology programs for CAR T-cell and biomarker-targeted therapies and announced plans for diagnostic and predictive tests.
Survey of Precision Oncology Programs Shows Rapid Pace of Advances a Major Challenge for Oncologists
Results from Precision Oncology News' survey indicate that keeping up with the fast-changing treatment landscape has overtaken reimbursement as the top challenge for doctors.